Dengue vaccine is a vaccine to prevent dengue fever in humans. The development of vaccine for dengue fever began as early as 1929, but has been hindered first by incomplete
knowledge of the disease pathogenesis, and later by the need to simultaneously create a stable immunity against all four dengue serotypes. Several vaccine candidates are in development including live attenuated, inactivated, DNA and subunit vaccines. Live attenuated vaccine candidates are the furthest along in development.
In 2016 a partially effective vaccine for dengue fever (Dengvaxia)
became commercially available in the Philippines and Indonesia. It has also been approved for us by Mexico, Brazil, El Salvador, Costa Rica, and Paraguay. In Indonesia it costs abou
t US$ 207 for the recommended three doses.